remdesivir

antiviral nucleotide analog

Also Known As:

(13C3)-GS-5734; 13C3 GS-5734; 13C3-GS-5734; 2-ethylbutyl (2S)-2-(((2R, 3S, 4R, 5R)-5-(4-aminopyrrolo(2,1-f) (1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl) methoxy)(phenoxy) phosphoryl) amino) propanoate; GS 5734; GS-465124; GS-5734; GS-829143; L-alanine, N-((S)-hydroxyphenoxyphosphinyl)-, 2-ethylbutyl ester, 6-ester with 2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-d-altrononitrile; Veklury

Networked: 1970 relevant articles (257 outcomes, 455 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cihlar, Tomas: 21 articles (02/2022 - 01/2017)
2.	Porter, Danielle P: 17 articles (02/2022 - 01/2020)
3.	Cao, Huyen: 10 articles (01/2022 - 01/2020)
4.	Feng, Joy Y: 10 articles (01/2022 - 01/2017)
5.	Gottlieb, Robert L: 9 articles (01/2022 - 01/2020)
6.	Beigel, John H: 8 articles (07/2022 - 01/2019)
7.	Mackman, Richard L: 8 articles (03/2022 - 01/2017)
8.	Babusis, Darius: 8 articles (02/2022 - 01/2017)
9.	Jordan, Robert: 8 articles (01/2022 - 01/2017)
10.	Mehta, Aneesh K: 7 articles (11/2022 - 11/2020)

Related Diseases

1.	COVID-19 11/27/2023 - "We found that remdesivir was effective in treating most COVID-19 patients in our study. " 01/01/2022 - "We have proven the utility of the systems in rapidly introducing mutations in nsp12 and studying their effect on the efficacy of remdesivir, which is used worldwide for the treatment of COVID-19. " 09/01/2023 - "Clinical trials also demonstrated the efficacy of remdesivir in other patient populations, including outpatients at high risk for progression to severe COVID-19, as well as hospitalized paediatric patients. " 12/01/2022 - "Several studies report that adult patients hospitalized with severe COVID-19 can be treated successfully with remdesivir (RDV). " 01/01/2020 - "Of which, one completed double blind, placebo controlled trial showed that remdesivir showed faster time to clinical improvement in severe COVID-19 patients compared to placebo though not found statistically significant. "
2.	Infections 10/05/2021 - "Remdesivir and high-titer convalescent plasma treatment were given, and the infection was eventually cleared after 335 days of infection. " 01/01/2020 - "Here, we tested the efficacy of prophylactic and therapeutic remdesivir treatment in a nonhuman primate model of MERS-CoV infection, the rhesus macaque. " 01/01/2023 - "Based on the observations made in this case, and the mechanistic rationale for use with iVDPV, there is strong justification for further clinical studies of remdesivir treatment as a potentially curative intervention in patients with iVDPV infection." 06/17/2022 - "In clinical trials, remdesivir decreased recovery time in hospitalized patients with SARS- CoV-2 and prevented hospitalization when given early during infection, despite not reducing nasal viral loads. " 11/01/2021 - "All patients admitted between February and May 2021 with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection confirmed by polymerase chain reaction testing from nasopharyngeal samples were included in the study, including those who received at least five-day treatment of remdesivir and who did not receive even a single dose of remdesivir. "
3.	Pneumonia (Pneumonitis) 09/15/2023 - "This prospective observation and monocentric study aim to verify the outcome (healing/death) of early use of remdesivir in pneumonia patients. " 05/01/2022 - "Our study suggests that the use of remdesivir could be useful in KT patients with SARS-CoV-2 pneumonia without side effects. " 05/01/2022 - "Our study suggests that the use of remdesivir could be useful in KT patients with SARS-CoV-2 pneumonia without side effects. " 11/01/2023 - "In this retrospective comparative study, we evaluated the effectiveness of remdesivir (RDSV) in patients with SARS-CoV-2 pneumonia. " 10/01/2023 - "Correction to: Changing patterns and clinical outcomes of hospitalized patients with COVID‑19 severe pneumonia treated with remdesivir according to vaccination status: results from a real‑world retrospective study."
4.	Severe Acute Respiratory Syndrome 01/01/2020 - "Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model. " 04/01/2020 - "This systemic review aimed at evaluating the available evidence on efficacy, safety to identify any promising role for compassionate use of remdesivir in patient suffered for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as re-purposeful use. " 06/01/2021 - "The effectiveness of remdesivir, a Food and Drug Administration-approved drug for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been repeatedly questioned during the current coronavirus disease 2019 (COVID-19) pandemic. " 10/01/2023 - "Remdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). " 11/01/2020 - "Remdesivir is a prodrug with in vitro activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). "
5.	Virus Diseases (Viral Diseases) 09/25/2023 - "Integrated continuous manufacturing of inhalable remdesivir nanoagglomerate dry powders: Design, optimization and therapeutic potential for respiratory viral infections." 01/09/2022 - "Since the beginning of corona virus disease 2019 (COVID-19) pandemic, there has been a widespread use of remdesivir in adults and children. " 05/01/2020 - "China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). " 01/01/2021 - "Studies to validate the efficacy of selected candidate COVID-19 drugs confirm that remdesivir strongly suppresses viral infection/replication. " 06/29/2020 - "We validated the efficacy of selected candidate COVID-19 drugs confirming that Remdesivir strongly suppressed viral infection/replication. "

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	Dexamethasone (Maxidex)
3.	favipiravir
4.	tocilizumab (atlizumab)
5.	baricitinib
6.	Hydroxychloroquine (Plaquenil)
7.	Ritonavir (Norvir)
8.	Oxygen (Dioxygen)
9.	Lopinavir
10.	Nucleosides

Related Therapies and Procedures

1.	Therapeutics
2.	Artificial Respiration (Mechanical Ventilation)
3.	Renal Dialysis (Hemodialysis)
4.	Length of Stay
5.	Noninvasive Ventilation